Exhibit 10.15 ADDENDUM TO MANUFACTURING AGREEMENT This ADDENDUM made effective as of the 26 October, 2001, is between SYNCO BIO PARTNERS B.V. (hereinafter "SYNCO") having an office at Paasheuvelweg 30, 1105 BJ Amsterdam Zuidoost, the Netherlands and NPS ALLELIX CORP., a corporation incorporated under the laws of Ontario and having as office at 6850 Goreway Drive, Mississauga, Ontario Canada L4V 1V7 (hereinafter "NPS ALLELIX"). WHEREAS, SYNCO and NPS ALLELIX entered into a Manufacturing Agreement, effective as of 17 May, 2001 (hereafter the "Agreement"); and WHEREAS, both NPS ALLELIX and SYNCO wish to continue the Agreement but in addition NPS ALLELIX now desires SYNCO to prepare a PTH Standard for NPS ALLELIX and SYNCO wishes to produce such PTH Standard for NPS ALLELIX. THEREFORE, the parties agree to the following addendum to the Agreement; 1. SYNCO shall produce a minimum of 4,500 vials of PTH Standard ("Vials of PTH Standard") in accordance with Appendix D. Each vial shall contain 0.3ml of a 2.1mg PTH/ml solution. The Vials of PTH Standard shal1 be prepared according to European GMP Guidelines. Batch Production Records shal1 be prepared by SYNCO and approved by NPS ALLELIX. 2. NPS ALLELIX shall pay SYNCO 31,500 Euros for the Vials of PTH Standard. On release of the Vials of PTH Standard by SYNCO to NPS ALLELIX, SYNCO shall invoice NPS ALLELIX in the amount of 31,500 Euros and NPS ALLELIX shall pay within thirty (30) days of such invoice. 3. The Vials of PTH Standard shall be filled by week 47 and tested as set out in Appendix D. SYNCO shall release the Batch Documents together with the Vials of PTH Standard to NPS within ten (10) weeks of filling the Vials of PTH Standard.
4. Unless explicitly altered by the Addendum, a1l terms of the Agreement as applicable shall apply to the production and release of the Vials of PTH Standard. Furthermore, this Addendum is not intended to alter any of the rights or obligations set out in the Agreement in the production of PTH under the Agreement. IN WITNESS WHEREOF, the parties hereto have caused this Addendum to be executed by their duly authorized representatives
SYNCO BIO PARTNERS B.V. NPS ALLELIX CORP.
/s/ Mic N. Hamers --------------------------Mic N. Hamers, Ph.D. Managing Director
/s/ Thomas B. Marriott ----------------------------Thomas B. Marriott, Ph.D. Vice President, Development Research
Back to Contents EXHIBIT 23.1 Consent of Independent Auditors The Board of Directors and Stockholders
Back to Contents EXHIBIT 23.1 Consent of Independent Auditors The Board of Directors and Stockholders NPS Pharmaceuticals, Inc. We consent to incorporation by reference in the registration statements (Nos. 33-79622, 333-17521, and 333-94269) on Forms S8, and (Nos. 333-41758 and 333-76532) on Forms S-3 of NPS Pharmaceuticals, Inc. of our report dated January 30, 2003, except as to note 14 which is as of June 4, 2003, relating to the consolidated balance sheets of NPS Pharmaceuticals, Inc. and subsidiaries (a development stage enterprise) as of December 31, 2002 and 2001, and the related consolidated statements of operations, stockholders’ equity and comprehensive income (loss), and cash flows for each of the years in the three-year period ended December 31, 2002, and for the period from October 22, 1986 (inception) to December 31, 2002, which report appears in the December 31, 2002, annual report on Form 10-K/A of NPS Pharmaceuticals, Inc. Our report refers to a change in the method of amortizing goodwill and intangible assets in 2002 and a change in the method of recognizing revenue on nonrefundable licensing fees in 2000. /s/ KPMG LLP Salt Lake City, Utah June 5, 2003